Community Board
Investment Case · Oct 8, 2026
Active
1

$NVO

LONG
Novo Nordisk A/S · NYSE
Pill Launch And Reset Valuation Favour Upside
RResearch Desk @research_desk Editorial Verified25 cases · 17% hit · -0.8% avgConviction 3/5 6-12 months, through Q3 2026 earnings (Nov 4) and the CagriSema FDA decision int
Thesis

After a roughly 40% drawdown, NVO trades near 11x forward earnings with a 4.8% yield. That prices in permanent share loss to Lilly, even though volumes are growing and the Wegovy pill is the strongest GLP-1 launch by volume in the US. A modest sentiment repair would be enough to rerate it.

Performance Since Publication
In the thesis direction
Return
+1.1%
At Publication
$38.26
Last
$38.67
To Target
+19.0%
STOP$34.50AT PUBLICATION$38.26PRICE TARGET$46.00LAST$38.67
Company Snapshot
Novo-Nordisk A/S
XNYS · United States
Large Cap
Market Cap
$168.9B
P/E (TTM)
—
Dividend Yield
—
Beta
—
Avg Volume
—
200-Day Avg
—
Next Earnings
—
Employees
69.5K

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care…

www.novonordisk.com
Price Levels
Entry
$37.00
Price Target
$46.00
Stop
$34.50
Catalysts
  1. 1Q3 results on Nov 4, 2026 (per Yahoo Finance): a third guidance raise would support the stabilisation case.
  2. 2FDA decision on CagriSema, expected late 2026, with a US launch guided for early 2027.
  3. 3Wegovy pill prescription trends and the Germany rollout, plus the Q4 etavopivat filing and the pending US decision on oral semaglutide 25 mg for type 2 diabe…
Key Risks
  1. 1Lilly's tirzepatide and orforglipron keep taking share, and CagriSema lost its head-to-head against Zepbound in February.
  2. 2US net pricing and Medicaid coverage may erode faster than volume grows, and management is guiding to a tougher second half.
  3. 3The pipeline credibility gap is widening (ziltivekimab failed in July, the denecimig FDA review was extended), and semaglutide patent expiries remain an over…
Read the Full Thesis
The market is pricing Novo as a melting franchise. The stock sits near $37.5 against a 52-week high of $64.16, at about 9x trailing and 11x forward earnings (per Yahoo Finance and CNBC, Oct 2026). The September 21 Capital Markets Day set peer-level sales growth to 2030 and a broadly stable margin, and the ADR fell about 8% to $39.80 (per Yahoo Finance and Cryptobasic). That target looks like a low bar for a company with the leading oral obesity product. The latest print supports the view that earnings are bottoming. Q2 adjusted sales rose 7% at constant exchange rates and adjusted operating profit rose 11% to DKK 33.4bn, against a company-compiled poll of DKK 28.7bn (per the Q2 6-K and Reuters, Aug 4). Full-year guidance was raised to 0% to -6% from -4% to -12%. The Wegovy pill has passed 5 million prescriptions and holds about 90% of US oral obesity scripts (per Quartr). Ex-US obesity sales grew 37%, so the decline is concentrated in US price, not demand. The macro angle is US drug pricing policy and Medicaid coverage. Management already guides to lower realized prices and a US sales decline, so much of the bad news is in the numbers. What has to be true: volume growth keeps offsetting price erosion, CagriSema launches on schedule in early 2027 (per CNBC, Sep 30), and guidance is not cut again.
Updates Since Publication
  1. Oct 13, 2026 · Price 38.36

    Weekly check-in: On Track. No thesis-breaking news; sell-side margin worries offset by pill and buyback support The past week brought no new results, guidance change or FDA action, so the Q2 raise and the CagriSema decision window (Q4 2026, no public PDUFA date as of Oct 7) are unchanged. Sell-side moves were mildly negative on earnings power: Citi cut its target to DKK 296 from DKK 310 and its 2027-2030 EPS growth to 9% from 12% on weak margin growth, and BMO cut to $40 from $47. Citi was constructive on the near-term top line, though. It sees Q3 sales about 1% above consensus and Wegovy pill sales about 16% above, helped by the UK launch, which fits the volume-offsets-price leg. The stock is about $38.4 and has bounced from the high-$37s, so the entry zone and the $34.5 stop are still coherent.

  2. Oct 20, 2026 · Price 38.42

    Weekly check-in: On Track. CagriSema data and buyback help; estimate cuts and Lilly oral news offset Nothing this week touches the core evidence: the Nov 4 Q3 report and the 0% to -6% guidance are unchanged. Per Reuters and Invezz, CagriSema showed about 25% average weight loss in women in a late-stage analysis, and the shares rose more than 2% on Tuesday. Analyst targets and estimates kept drifting lower, so the margin worry is still there. The thesis depends on Q3 confirming stabilisation, and that is still two weeks away.

The Other Side

Disagree? Make the opposite case with your own levels. Both get scored, so the debate gets a winner.

Track This Case

Copy it into your own account, adjust it to your view, and get an alert when the price reaches its levels.

Discussion
Do You Agree With @research_desk?
agreedisagree
No one has weighed in yet. Be the first. A stance is a reader's view, not advice.
Be specific and civil. No promotion or price-pumping. Comments are checked before they appear. Guidelines

No comments yet. Start the discussion with the point you'd want the author to answer.

Investment case published by @research_desk. It reflects the author’s own views at the time of publication and is for information only. It is not investment advice or a recommendation to buy or sell any security. Prices and company data are delayed and may be inaccurate. User content is not verified. Editorial cases are written by our research desk with AI research assistance and reviewed by the team. · How we measure performance

More investment cases by @research_desk·Write Your Own Case
Long $NVO | Investment Case. After a roughly 40% drawdown, NVO trades near 11x forward earnings with a 4.8% yield. That prices in permanent share loss to Lilly, even though volumes are growing and the Wegov…